Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immune-Marker Platform for Patients With Advanced Lung Cancer

NCT07150598 is registered in ClinicalTrials.gov with Technische Universität Dresden as lead sponsor.

NCT NCT07150598
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07150598 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immune-Marker Platform for Patients With Advanced Lung Cancer
Lead sponsor
Technische Universität Dresden
Phase
Observational
Overall status
Not yet recruiting
Start date
September 1, 2025
Completion date
June 1, 2027
Enrollment
500 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc (advanced non-small cell lung cancer), nsclc non-small cell lung cancer, nsclc stage iiib~iv